NCT06079372: An ongoing trial by Alexion Pharmaceuticals, Inc.
This trial is ongoing. It must report results 7 months, 1 week from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06079372 |
|---|---|
| Title | A Phase 3, Randomized, Open-label, Parallel-arm, Active-controlled, Multicenter Study to Evaluate Safety and Efficacy of ALXN1850 Versus Asfotase Alfa Administered Subcutaneously in Pediatric Participants (2 to < 12 Years of Age) With Hypophosphatasia (HPP) Previously Treated With Asfotase Alfa |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | April 2, 2024 |
| Completion date | July 23, 2025 |
| Required reporting date | July 23, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |